Press Releases Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.2 ^USD	-0.31%		-8.83%	+4.97%

May. 16	Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes	CI
May. 16	Aileron Therapeutics, Inc. Announces Executive Changes	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	May. 15	AQ
Aileron Therapeutics to Present at Two Upcoming Investor Conferences	May. 06	AQ
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million	May. 03	AQ
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million	May. 01	AQ
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)	May. 01	AQ
Aileron Therapeutics : Corporate Presentation April 2024	Apr. 15	PU
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Apr. 15	AQ
Aileron Therapeutics : Management Change/Compensation - Form 8-K	Mar. 29	PU
Aileron Therapeutics Announces CEO Transition	Mar. 12	AQ
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event	Feb. 15	AQ
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024	Feb. 01	AQ
Aileron Therapeutics : Merger Announcement	23-10-31	PU
Aileron Therapeutics Announces Acquisition of Lung Therapeutics	23-10-31	PR
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-08	AQ
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-20	AQ
AILERON THERAPEUTICS INC : Costs Associated with Exit or Disposal Activities, Other Events (form 8-K)	23-02-23	AQ
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives	23-02-21	AQ
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements	22-11-30	AQ
AILERON THERAPEUTICS INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22-11-10	AQ
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split	22-11-10	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Press Releases

Filters